Skip to content
lifestyle.capitolhilltimes.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Thryv Therapeutics Inc.
Thryv Therapeutics to Participate in UBS, RBC Capital Markets, and Jefferies Healthcare Conferences
May 12, 2026
Thryv Therapeutics Commences Patient Dosing in Wave II Clinical Study for Long QT Syndrome and Receives FDA Fast Track Designation for THRV-1268
April 22, 2026
Thryv Therapeutics Launches Pivotal Wave II Phase 2/3 Study in Long QT Syndrome Type 2
January 14, 2026
Thryv Therapeutics Announces Positive Phase 1 Results of THRV-1268 in Obese Participants
December 17, 2025